Meeting Information - The first extraordinary general meeting of shareholders for 2025 is scheduled for September 22, 2025, at 14:00 [1] - The meeting will be held in the conference room of Kingchem (Liaoning) Life Science Technology Co., Ltd., combining on-site voting and online voting [1][2] - Online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 09:15 to 15:00 on the same day [1][2] Voting Procedures - Shareholders can participate in the meeting either in person or by proxy, with the requirement to register beforehand [2][5] - Voting can be conducted through the Shenzhen Stock Exchange trading system or the internet voting system, with specific time slots designated for each [2][4] - Duplicate votes will be resolved by considering the first vote cast [2][3] Agenda Items - The meeting will review several proposals, including changing the funding method for certain projects from loans to capital increases to subsidiaries and using idle funds for cash management [3][4] - Proposals requiring special resolutions must receive approval from more than two-thirds of the voting rights held by attending shareholders [4] - Related shareholders are required to abstain from voting on specific proposals to ensure fairness [4] Registration and Attendance - Institutional shareholders must provide identification and authorization documents for registration, while individual shareholders need to present their ID [5][6] - Registration can also be done via mail or email for shareholders unable to attend in person [5][6] Contact Information - For inquiries, shareholders can contact Wang Qi at 0418-6327768 or via email at bod.office@kingchemchina.com [6]

Core Viewpoint - Kingchem (Liaoning) Life Science Co., Ltd. reported significant growth in its financial performance for the first half of 2025, with notable increases in revenue and net profit compared to the same period last year [1][2]. Financial Performance - The company's operating revenue reached CNY 348,402,686.20, marking a 32.98% increase from CNY 261,993,494.68 in the previous year [1]. - Net profit attributable to shareholders was CNY 71,760,596.20, representing a substantial increase of 123.61% from CNY 32,091,742.08 [1]. - The net profit after deducting non-recurring gains and losses was also significantly higher, although specific figures were not provided [1]. - The net cash flow from operating activities was CNY 74,718,846.77, up 14.47% from CNY 65,272,793.61 [1]. - Basic and diluted earnings per share both increased to CNY 0.60, a rise of 122.22% from CNY 0.27 [1]. Asset and Equity Position - Total assets at the end of the reporting period were CNY 2,303,635,543.06, reflecting a 1.78% increase from CNY 2,263,389,145.02 at the end of the previous year [2]. - Net assets attributable to shareholders increased to CNY 2,173,929,045.13, a growth of 1.17% from CNY 2,148,819,290.03 [2]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 13,817 [2]. - The largest shareholder, Kingchem (China) Holding LLC, holds 48.66% of the shares, with FUMIN WANG and LIANPING WU having a controlling interest [3][4]. - There were no changes in the controlling shareholder or actual controller during the reporting period [4].

Core Viewpoint - The report highlights the financial performance and operational capabilities of Kingchem (Liaoning) Life Science Co., Ltd. for the first half of 2025, showcasing significant growth in revenue and net profit, alongside a focus on CDMO services in the life sciences sector [1][3][5]. Financial Performance - The company's revenue for the reporting period reached approximately 348.40 million yuan, representing a 32.98% increase compared to the same period last year, which was approximately 261.99 million yuan [6][16]. - The net profit attributable to shareholders increased by 122.22%, with basic and diluted earnings per share rising to 0.60 yuan from 0.27 yuan [6][16]. - The total assets at the end of the reporting period were approximately 2.30 billion yuan, a 1.78% increase from the previous year [6][16]. Business Overview - Kingchem operates as a small molecule CDMO service provider, catering to global pharmaceutical and biotechnology companies by offering custom development and manufacturing services [8][9]. - The company specializes in the synthesis of pharmaceutical intermediates and active pharmaceutical ingredients (APIs), focusing on enhancing the efficiency and reducing the costs of drug development for its clients [9][10]. Competitive Advantages - The company has established a global presence with production and R&D facilities in both China and the United States, allowing for better responsiveness to client needs and market demands [11][12]. - Kingchem's expertise in fluorinated compounds and a comprehensive range of chemical synthesis capabilities position it as a competitive player in the CDMO market [13][14]. Client Relationships - The company has built a strong client base, including major international pharmaceutical companies and innovative biotech firms, which enhances its business sustainability and growth potential [11][13]. - Long-term partnerships with clients are fostered through high-quality service and adherence to stringent quality management systems, which are critical in the pharmaceutical industry [14]. Research and Development - Kingchem has invested in R&D to support its service offerings, with a focus on developing complex chemical compounds and optimizing production processes [9][13]. - The company has a pipeline of clinical-stage projects, which could lead to significant revenue growth if successful products are brought to market [14].

Meeting Overview - The second board meeting of King Kai (Liaoning) Life Science Co., Ltd. was held on August 22, 2025, with all 7 directors present, including 2 via communication [1] - The meeting was chaired by Chairman Fumin Wang and complied with relevant laws and regulations [1] Financial Reporting - The board approved the 2025 semi-annual report, confirming it accurately reflects the company's financial status and operational results without any misleading statements [2] - The report on the management and use of raised funds was also approved, indicating compliance with regulations and accurate reporting [2] Compensation Adjustments - The board agreed to adjust the independent director's allowance from 100,000 yuan to 120,000 yuan per year, effective upon shareholder approval [3] Fund Management - The board approved a change in the method of using raised funds from loans to capital injection into subsidiaries, aimed at improving fund efficiency and protecting shareholder interests [3] - The use of idle raised funds for cash management was also approved, ensuring it does not affect project construction or normal operations [5] Governance Enhancements - The board approved revisions to the company's articles of association and internal governance rules to enhance corporate governance and protect investor rights [6][7] - New internal governance systems were established to further improve the company's governance structure [9] Capital Injection - The board approved the use of self-owned funds to increase capital in Kingchem Life Science LLC for the construction of Kingchem Laboratories Inc., supporting the company's international competitiveness [10] Upcoming Meetings - The company plans to hold its first temporary shareholders' meeting on September 22, 2025, combining on-site and online voting [10]

证券日报网讯 8月22日晚间，金凯生科发布公告称，公司于2025年8月22日召开第二届董事会第八次会 议、第二届监事会第八次会议，分别审议通过了《关于使用部分闲置募集资金（含超募资金）及自有资 金进行现金管理的议案》，同意公司在确保不影响募集资金投资项目建设需要和公司正常经营、并有效 控制风险的前提下，公司拟使用不超过人民币9亿元（含本数）的暂时闲置募集资金（含超募资金）及 不超过人民币7亿元（含本数）的自有资金进行现金管理。上述额度的有效期自公司股东会审议通过之 日起12个月内有效。在上述额度和期限范围内，资金可以循环滚动使用。暂时闲置募集资金（含超募资 金）现金管理到期后将及时归还至募集资金专户。 （文章来源：证券日报） ...

证券日报网讯 8月22日晚间，金凯生科发布公告称，2025年半年度公司实现营业收入348，402，686.20 元，同比增长32.98%；归属于上市公司股东的净利润为71，760，596.20元，同比增长123.61%。 （文章来源：证券日报） ...

证券日报网讯 8月22日晚间，金凯生科发布公告称，公司第二届董事会第八次会议审议通过了《关于调 整第二届董事会独立董事津贴的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The company announced that its second supervisory board meeting approved several proposals, including changing the implementation of certain fundraising projects from borrowing funds to increasing capital in subsidiaries using self-owned funds [2]

证券日报网讯金凯生科（301509）8月22日在互动平台回答投资者提问时表示，截至2025年8月20日，公 司股东数为14135户。 ...

格隆汇8月22日丨金凯生科(301509.SZ)公布，公司于2025年8月22日召开的第二届董事会第八次会议和第二届监事会第八次会议分别审议通过了《关于使用自有资金向子公司Kingchem Li ...